Status:
UNKNOWN
Characterisation of Gene Variants in the Angiogenic Pathway
Lead Sponsor:
National University Hospital, Singapore
Conditions:
Solid Tumors
Eligibility:
All Genders
18+ years
Brief Summary
Anti-angiogenic targeted therapies are used in a wide range of solid tumors including NSCLC, breast cancer, GISTs, CRC, renal cell carcinoma and hepatocellular carcinoma. Somatic mutations in genes re...
Detailed Description
Angiogenesis plays a key role in the process of tumour growth and metastases. Anti-angiogenic targeted therapies are currently used in a wide range of solid tumors including lung, breast, colorectal, ...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Anti-angiogenic targeted therapies are used in a wide range of solid tumors including NSCLC, breast cancer, GISTs, CRC, renal cell carcinoma and hepatocellular carcinoma
Exclusion
Key Trial Info
Start Date :
March 1 2007
Trial Type :
OBSERVATIONAL
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00716287
Start Date
March 1 2007
Last Update
January 14 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National University Hospital
Singapore, Singapore